Business · 25/10/2019Updated: 10/17/2026 · 1 min read
FDA Releases Draft Guidance on Postmarketing Studies and Clinical Trials
Summary
The FDA has released a draft guidance for industry on postmarketing studies and clinical trials, revising the previous guidance to consider multiple factors and reflect new provisions enacted under the SUPPORT for Patients and Communities Act.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →